Evidence map›Paper›PMID 42004832›Full record

ArticleEuropean urology open science2026

A Study to Evaluate Efficacy and Safety of Hydeal Cyst Intravesical Instillations in Non-muscle Invasive Bladder Cancer Patients Treated With Intravesical Chemotherapy or Immunotherapy.

Francesco Callegarin, Antonio Amodeo, Francesco Claps, Alessandro Crestani, Alessandro Antonelli, Gian Maria Busetto, Fabrizio Dal Moro, Nicola Zanovello, Nicola Pavan, Giovanna Magni and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European urology open science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Francesco CallegarinClinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Antonio AmodeoOncological Urology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Francesco ClapsOncological Urology, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Alessandro CrestaniDepartment of Urology, Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy.
Alessandro AntonelliDepartment of Urology, University of Verona, Verona, Italy.
Gian Maria BusettoDepartment of Medical and Surgical Sciences, Ospedale Riuniti, University of Foggia, Foggia, Italy.
Fabrizio Dal MoroUrology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Nicola ZanovelloUrology Unit, Madre Teresa di Calcutta Hospital, AULSS 6, Ospedali Riuniti Padova Sud, Monselice, Italy.
Nicola PavanUrology Clinic, Department of Precision Medicine in Medical, Surgical and Critical Care, University of Palermo, Palermo, Italy.
Giovanna MagniClinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Ilaria BuranClinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Luca Di GianfrancescoDepartment of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy.
Gian Luca De SalvoClinical Research Unit, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Angelo PorrecaDepartment of Urology, Humanitas Gavazzeni Hospital, Bergamo, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In non-muscle-invasive bladder cancer (NMIBC), patients undergo adjuvant local therapies such as chemotherapy (mitomycin C [MMC]) or immunotherapy (Bacillus Calmette-Guérin [BCG]) to reduce the risk of relapse and local/systemic progression. The main issue related to these topic therapies is their toxicity that is mainly local with rare systemic events. Hyaluronic acid is recommended in cases where it is necessary to restore and/or protect the layer of glycosaminoglycans damaged by local therapies. The Hydeal Cyst (HC) trial is a multicenter, randomized, controlled, open-label clinical investigation that aims to evaluate if HC intravesical instillations could mitigate lower urinary tract symptoms (LUTS) and improve oncological outcomes. Overall, 200 patients affected by NMIBC (naïve or recurrent) underwent transurethral resection (TURB/re-TURB when indicated) in the 4 wk before enrolment, and candidates to BCG or MMC intravesical induction therapy with an International Prostrate Symptom Score ≤10 will be randomized to HC intravesical instillations or control. The primary objective is to investigate if multiple HC intravesical instillations decrease the LUTS. Secondary objectives are recurrence-free survival, progression-free survival, safety, and quality of life. This study has potential to change the current LUTS treatment approaches, reducing the rate of early treatment discontinuation and thereby leading to a higher rate of therapeutic response.

Identifiers

PMID42004832
PMCPMC13087740

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.